Mosaic Chromosomal Alterations Are Associated With Increased Lung Cancer Risk: Insight From the INTEGRAL-ILCCO Cohort Analysis.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
08 2023
Historique:
received: 14 03 2023
revised: 21 04 2023
accepted: 01 05 2023
pmc-release: 01 08 2024
medline: 24 7 2023
pubmed: 8 5 2023
entrez: 7 5 2023
Statut: ppublish

Résumé

Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared with CH-related somatic mutations. A few recent studies indicated their potential link with nonhematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with 18,221 lung cancer cases and 14,825 cancer-free controls. We identified a comprehensive list of autosomal mCAs, ChrX mCAs, and mosaic ChrY (mChrY) losses from these samples. Autosomal mCAs were detected in 4.3% of subjects, in addition to ChrX mCAs in 3.6% of females and mChrY losses in 9.6% of males. Multivariable logistic regression analysis indicated that the presence of autosomal mCAs in white blood cells was associated with an increased lung cancer risk after adjusting for key confounding factors, including age, sex, smoking status, and race. This association was mainly driven by a specific type of mCAs: copy-neutral loss of heterozygosity on autosomal chromosomes. The association between autosome copy-neutral loss of heterozygosity and increased risk of lung cancer was further confirmed in two major histologic subtypes, lung adenocarcinoma and squamous cell carcinoma. In addition, we observed a significant increase of ChrX mCAs and mChrY losses in smokers compared with nonsmokers and racial differences in certain types of mCA events. Our study established a link between mCAs in white blood cells and increased risk of lung cancer.

Identifiants

pubmed: 37150255
pii: S1556-0864(23)00527-0
doi: 10.1016/j.jtho.2023.05.001
pmc: PMC10435278
mid: NIHMS1922894
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1003-1016

Subventions

Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA269764
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA227996
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Références

Cell Signal. 2015 Feb;27(2):326-39
pubmed: 25460043
Hum Mol Genet. 2010 Dec 15;19(24):4948-54
pubmed: 20876614
Nat Med. 2021 Nov;27(11):1921-1927
pubmed: 34663986
Cell Rep. 2018 Apr 17;23(3):852-865
pubmed: 29669289
Nat Genet. 2012 May 06;44(6):651-8
pubmed: 22561519
Nature. 2018 Jul;559(7714):350-355
pubmed: 29995854
Nat Genet. 2022 Aug;54(8):1167-1177
pubmed: 35915169
Nat Genet. 2012 May 06;44(6):642-50
pubmed: 22561516
Nature. 2007 Mar 8;446(7132):153-8
pubmed: 17344846
Oncogene. 2009 Dec 10;28(49):4364-74
pubmed: 19767769
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135
pubmed: 27697780
Nat Genet. 2022 Aug;54(8):1155-1166
pubmed: 35835912
Nature. 2004 Dec 2;432(7017):635-9
pubmed: 15577913
Nature. 2020 Aug;584(7819):130-135
pubmed: 32581364
J Hum Genet. 2021 Sep;66(9):879-885
pubmed: 34321609
Brain Res. 2019 Oct 15;1721:146345
pubmed: 31348909
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Nat Commun. 2017 Apr 24;8:15059
pubmed: 28436416
J Thorac Oncol. 2019 Jan;14(1):37-44
pubmed: 30267841
Science. 2022 Jul 15;377(6603):292-297
pubmed: 35857592
Science. 2019 Nov 1;366(6465):
pubmed: 31672865
Nat Med. 2021 Jun;27(6):1012-1024
pubmed: 34099924
Neuropsychiatr Dis Treat. 2018 Aug 20;14:2115-2122
pubmed: 30154659
Nature. 2019 Nov;575(7784):652-657
pubmed: 31748747
J Exp Clin Cancer Res. 2013 May 20;32:29
pubmed: 23688269
Cancer Res. 2019 Feb 1;79(3):461-466
pubmed: 30510122
Nature. 2020 Aug;584(7819):136-141
pubmed: 32581363
Cancer Res. 1997 May 1;57(9):1664-7
pubmed: 9135004
Sci Rep. 2020 Feb 27;10(1):3655
pubmed: 32108144
Nat Genet. 2010 Sep;42(9):794-800
pubmed: 20694012
Blood. 2009 Aug 27;114(9):1859-63
pubmed: 19571318
Mol Ther Oncolytics. 2020 May 26;17:562-570
pubmed: 32637574
Nat Neurosci. 2021 Feb;24(2):197-203
pubmed: 33432194
Oncogene. 2009 Nov 26;28(47):4189-200
pubmed: 19734946
Nat Genet. 2016 May;48(5):563-8
pubmed: 27064253
Nat Genet. 2017 Jan;49(1):10-16
pubmed: 27869828
Nat Genet. 2017 Jul;49(7):1126-1132
pubmed: 28604730
Nat Genet. 2014 Jun;46(6):624-8
pubmed: 24777449
Nat Commun. 2016 Jun 13;7:11843
pubmed: 27291797
Exp Ther Med. 2020 Jul;20(1):385-394
pubmed: 32565927
Genome Biol Evol. 2015 Nov 11;7(12):3239-48
pubmed: 26560338
Oncogene. 2019 Oct;38(44):6985-7001
pubmed: 31409903
Biochem Biophys Res Commun. 2016 Jan 22;469(4):1000-5
pubmed: 26713367
Nat Genet. 2017 May;49(5):674-679
pubmed: 28346444
Leukemia. 2018 Jul;32(7):1609-1620
pubmed: 29472722
Science. 2015 Jan 2;347(6217):81-3
pubmed: 25477213
Hum Genet. 2020 Apr;139(4):421-446
pubmed: 32020362
Cancer Cell Int. 2020 Aug 12;20:389
pubmed: 32831649
Sci Rep. 2018 Aug 17;8(1):12316
pubmed: 30120341
Nat Commun. 2019 Nov 28;10(1):5436
pubmed: 31780650

Auteurs

Chao Cheng (C)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Wei Hong (W)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas.

Yafang Li (Y)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Xiangjun Xiao (X)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas.

James McKay (J)

Section of Genetics, International Agency for Research on Cancer, WHO, Lyon, France.

Younghun Han (Y)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas.

Jinyoung Byun (J)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas.

Bo Peng (B)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas.

Demetrios Albanes (D)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Stephen Lam (S)

Department of Integrative Oncology, University of British Columbia, Vancouver, British Columbia, Canada.

Adonina Tardon (A)

Public Health Department, University of Oviedo, ISPA and CIBERESP, Asturias, Spain.

Chu Chen (C)

Program in Epidemiology, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.

Stig E Bojesen (SE)

Department of Clinical Biochemistry, Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Maria T Landi (MT)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Mattias Johansson (M)

Section of Genetics, International Agency for Research on Cancer, WHO, Lyon, France.

Angela Risch (A)

Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany; University of Salzburg and Cancer Cluster Salzburg, Salzburg, Austria.

Heike Bickeböller (H)

Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.

H-Erich Wichmann (HE)

Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany.

David C Christiani (DC)

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Gad Rennert (G)

Clalit National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.

Susanne Arnold (S)

University of Kentucky, Markey Cancer Center, Lexington, Kentucky.

Gary Goodman (G)

Swedish Cancer Institute, Seattle, Washington.

John K Field (JK)

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.

Michael P A Davies (MPA)

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.

Sanjay S Shete (SS)

Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Loic Le Marchand (L)

Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.

Geoffrey Liu (G)

University Health Network- The Princess Margaret Cancer Centre, Toronto, California.

Rayjean J Hung (RJ)

Luenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

Angeline S Andrew (AS)

Department of Epidemiology, Dartmouth College, Hanover, New Hampshire; Department of Community and Family Medicine, Dartmouth College, Hanover, New Hampshire.

Lambertus A Kiemeney (LA)

Radboud University Medical Center, Nijmegen, The Netherlands.

Meng Zhu (M)

Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.

Hongbing Shen (H)

Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.

Shan Zienolddiny (S)

National Institute of Occupational Health, Oslo, Norway.

Kjell Grankvist (K)

Department of Medical Biosciences, Umeå University, Umeå, Sweden.

Mikael Johansson (M)

Department of Radiation Sciences, Umeå University, Umeå, Sweden.

Angela Cox (A)

Academic Unit of Clinical Oncology University of Sheffield, Weston Park Hospital, Whitham Road, Sheffield, United Kingdom.

Yun-Chul Hong (YC)

Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Jian-Min Yuan (JM)

University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania.

Philip Lazarus (P)

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.

Matthew B Schabath (MB)

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Melinda C Aldrich (MC)

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Paul Brennan (P)

Section of Genetics, International Agency for Research on Cancer, WHO, Lyon, France.

Yong Li (Y)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Olga Gorlova (O)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Ivan Gorlov (I)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Christopher I Amos (CI)

Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas. Electronic address: chris.amos@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH